Ghaffarian Rasa, Muro Silvia
Fischell Department of Bioengineering, University of Maryland.
J Vis Exp. 2013 Oct 17(80):e50638. doi: 10.3791/50638.
Sub-micrometer carriers (nanocarriers; NCs) enhance efficacy of drugs by improving solubility, stability, circulation time, targeting, and release. Additionally, traversing cellular barriers in the body is crucial for both oral delivery of therapeutic NCs into the circulation and transport from the blood into tissues, where intervention is needed. NC transport across cellular barriers is achieved by: (i) the paracellular route, via transient disruption of the junctions that interlock adjacent cells, or (ii) the transcellular route, where materials are internalized by endocytosis, transported across the cell body, and secreted at the opposite cell surface (transyctosis). Delivery across cellular barriers can be facilitated by coupling therapeutics or their carriers with targeting agents that bind specifically to cell-surface markers involved in transport. Here, we provide methods to measure the extent and mechanism of NC transport across a model cell barrier, which consists of a monolayer of gastrointestinal (GI) epithelial cells grown on a porous membrane located in a transwell insert. Formation of a permeability barrier is confirmed by measuring transepithelial electrical resistance (TEER), transepithelial transport of a control substance, and immunostaining of tight junctions. As an example, ~200 nm polymer NCs are used, which carry a therapeutic cargo and are coated with an antibody that targets a cell-surface determinant. The antibody or therapeutic cargo is labeled with (125)I for radioisotope tracing and labeled NCs are added to the upper chamber over the cell monolayer for varying periods of time. NCs associated to the cells and/or transported to the underlying chamber can be detected. Measurement of free (125)I allows subtraction of the degraded fraction. The paracellular route is assessed by determining potential changes caused by NC transport to the barrier parameters described above. Transcellular transport is determined by addressing the effect of modulating endocytosis and transcytosis pathways.
亚微米级载体(纳米载体;NCs)通过改善药物的溶解性、稳定性、循环时间、靶向性和释放来提高药物疗效。此外,穿越体内的细胞屏障对于将治疗性NCs口服递送至循环系统以及从血液转运至需要干预的组织至关重要。NCs穿越细胞屏障的方式有:(i)细胞旁途径,即通过暂时破坏连接相邻细胞的连接结构;(ii)跨细胞途径,即物质通过内吞作用内化,穿过细胞体,并在细胞另一侧表面分泌(转胞吞作用)。将治疗药物或其载体与特异性结合参与转运的细胞表面标志物的靶向剂偶联,可以促进药物穿越细胞屏障。在此,我们提供了测量NCs穿越模型细胞屏障的程度和机制的方法,该模型细胞屏障由生长在Transwell小室多孔膜上的单层胃肠道(GI)上皮细胞组成。通过测量跨上皮电阻(TEER)、对照物质的跨上皮转运以及紧密连接的免疫染色来确认通透性屏障的形成。例如,使用携带治疗性货物并包被有靶向细胞表面决定簇的抗体的约200 nm聚合物NCs。抗体或治疗性货物用(125)I进行放射性同位素标记,将标记的NCs在不同时间段添加到细胞单层上方的上室中。可以检测与细胞相关和/或转运至下层小室的NCs。测量游离(125)I可减去降解部分。通过确定NCs转运对上述屏障参数引起的潜在变化来评估细胞旁途径。通过研究调节内吞作用和转胞吞作用途径的影响来确定跨细胞转运。